Latest News in the pharma Industry

Research & Development

Merck initiates Phase III study of MSB11022, a proposed biosimilar of adalimumab, in chronic plaque psoriasis

Merck initiates Phase III study of MSB11022, a proposed biosimilar of adalimumab, in chronic plaque psoriasis

2 Mar 2016

Study will evaluate efficacy, safety and immunogenicity of adalimumab biosimilar candidate MSB11022 compared with Humira.

Read more 
Concert Pharmaceuticals announces CTP-656 solid dose Phase I results confirmed superior pharmacokinetic profile to Kalydeco

Concert Pharmaceuticals announces CTP-656 solid dose Phase I results confirmed superior pharmacokinetic profile to Kalydeco

2 Mar 2016

Concert is using this tablet formulation of CTP-656 in its ongoing multiple ascending dose Phase I clinical trial and intends to use the same formulation in a Phase II clinical trial.

Read more 
Sobi and Biogen receive positive opinion from CHMP for Alprolix (rFIXFc) for the treatment of hemophilia B

Sobi and Biogen receive positive opinion from CHMP for Alprolix (rFIXFc) for the treatment of hemophilia B

2 Mar 2016

If approved, Alprolix would be among the first therapies in the European Union (EU) to offer people living with hemophilia B prolonged protection against bleeding episodes with prophylactic dosing intervals.

Read more 
Acticor Biotech selects Catalent GPEx Cell Line Development Technology to develop ACT-017

Acticor Biotech selects Catalent GPEx Cell Line Development Technology to develop ACT-017

1 Mar 2016

Acticor Biotech is developing an antibody fragment (Fab) considered as a first-in-class anti-thrombotic agent without bleeding risk in the primary treatment of ischemic strokes.

Read more 
Company pioneering nanotechnology to bring innovative medicines that make a real difference

Company pioneering nanotechnology to bring innovative medicines that make a real difference

1 Mar 2016

Blueberry Therapeutics is set to create safe, effective “nanomedicines” to treat a number of unmet clinical needs.

Read more 
Chem-Space launches to provide largest global chemical database and search tool

Chem-Space launches to provide largest global chemical database and search tool

1 Mar 2016

Chem-space.com online searchable marketplace features over 15 million compounds.

Read more 
Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss

Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss

29 Feb 2016

NIH-funded clinical trial shows Eylea, Avastin, and Lucentis perform similarly when vision loss is mild.

Read more 
True North Therapeutics receives Orphan Drug Designation in the EU for TNT009 for the treatment of autoimmune hemolytic anemia, including CAD

True North Therapeutics receives Orphan Drug Designation in the EU for TNT009 for the treatment of autoimmune hemolytic anemia, including CAD

29 Feb 2016

Top-line Phase Ib data in patients with CAD expected in mid-2016.

Read more 
FDA approves new indication for Novartis drug Afinitor for progressive, nonfunctional GI and lung neuroendocrine tumours

FDA approves new indication for Novartis drug Afinitor for progressive, nonfunctional GI and lung neuroendocrine tumours

28 Feb 2016

In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NET.

Read more 
Parkinson’s disease market set to hit $3.2 billion by 2021 as search for cure continues

Parkinson’s disease market set to hit $3.2 billion by 2021 as search for cure continues

28 Feb 2016

GBI Research report says that despite steady market growth, various unmet needs remain and a cure is yet to be found.

Read more 
FDA approves Genentech’s Gazyva for certain people with previously treated follicular lymphoma

FDA approves Genentech’s Gazyva for certain people with previously treated follicular lymphoma

26 Feb 2016

This is the second FDA approval for Gazyva based on a positive Phase III study.

Read more 
FDA accepts and grants Priority Review for Avycaz sNDA

FDA accepts and grants Priority Review for Avycaz sNDA

25 Feb 2016

Application seeks to expand Avycaz label to include Phase III clinical data for the treatment of complicated intra-abdominal infections , in combination with metronidazole.

Read more